Cann Group (ASX:CAN) - CEO, Peter Crock
CEO, Peter Crock
Source: Cannabis Club Australia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical cannabis company Cann Group (CAN) has announced that investor Aurora Cannabis has dropped its stake in the company
  • Aurora sold its 11.84 per cent shareholding in Cann via off-market trades to a small number of buyers
  • Aurora said its plan to sell is consistent with its current strategic priorities
  • Nevertheless, Cann has reassured shareholders that Aurora’s decision will not impact its business plans
  • On the market today, Cann is down 7.14 per cent, trading for 39 cents per share

Medical cannabis company Cann Group (CAN) has announced that investor Aurora Cannabis has dropped its stake in the company.

On Friday, Aurora sold its 11.84 per cent shareholding in Cann via off-market trades to a small number of buyers.

Aurora said its plan to sell is consistent with its current strategic priorities.

Nevertheless, Cann has reassured shareholders that Aurora’s decision will not impact its business plans.

Currently, the company is “developing a growing and diversified supply base with business to business (B2B) customers in Australia and overseas and proceeding with plans to expand its manufacturing capacity.”

In August, the company’s 2020 financial year results came out. Cann’s full-year revenue slipped 56 per cent to $1.86 million compared to the previous financial year.

With the Mildura facility expansion, Cann is expecting around $15 million in revenue for the 2021 financial year.

On the market today, Cann is down 7.14 per cent, trading for 39 cents per share at 12:31pm AEDT.

CAN by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system